In all five primary AML samples, mebendazole treatment induced significant differentiation in the leukemia blasts as evidenced by increased expression of myeloid markers (CD11b, CD11c, and CD14) (Fig. 4a,c and Supplementary Fig. S4a). This evidence concerns the gene CD14 and acute myeloid leukemia.